- The key vendors in the Global Congestive Heart Failure Drugs Market 2015-2019 are AstraZeneca plc, Bristol-Myers Squibb Co., GlaxoSmithKline plc (GSK), Merck & Co. Inc., Mylan Inc., Novartis AG, Pfizer Inc., Sanofi SA and Valeant Pharmaceuticals International Inc.
London, 20 January 2015: TechNavio, an independent tech-focused global research firm, has announced the publication of its market research report on the Global Congestive Heart Failure Drugs Market 2015-2019. One major trend witness in this market is the increase in awareness. The acceptability of congestive heart failure drugs is expected to increase because of the increase in public awareness. Patients and physicians are becoming more aware about congestive heart failure. The Global Congestive Heart Failure Drugs market is expected to grow at a CAGR of 9.47 percent during the forecast period of 2014-2019.
“The future of congestive heart failure treatment lies in new technologies such as biotechnology and genomics,” says Faisal Ghaus, Vice President of TechNavio Research.
“The genes associated with congestive heart failure can be identified in fetuses using these new technologies, and new treatments such as treatments that address the endothelium and stem cell therapy are under development.”
To define the market conditions in the next 3-4 years, TechNavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
